UCB Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and | Outperform |
16
|
$770.00 | Buy/Sell | $636.99 | 13.96% | 9 | $693.31B |
| JNJ | Johnson & Johnson | Outperform |
9
|
$154.64 | Buy/Sell | $174.55 | 9.93% | 3 | $372.17B |
| MRK | Merck | Outperform |
2
|
$131.19 | Buy/Sell | $130.51 | 9.00% | 11 | $332.28B |
| ABBV | AbbVie | Outperform |
9
|
$166.42 | Buy/Sell | $178.42 | 9.66% | 11 | $293.88B |
| TMO | Thermo Fisher Scientific | Outperform |
10
|
$595.30 | Buy/Sell | $591.94 | 4.15% | 1 | $227.24B |
| NOVN | Novartis | Hold |
10
|
CHF93.37 | Buy/Sell | CHF105.00 | 15.26% | 9 | CHF190.51B |
| AMGN | Amgen | Outperform |
4
|
$312.47 | Buy/Sell | $303.65 | 2.41% | 8 | $167.62B |
| SAN | Sanofi | Outperform |
16
|
89.17€ | Buy/Sell | 102.80€ | 22.80% | 9 | 111.47€B |
| CSL | CSL | Outperform |
12
|
$280.00 | Buy/Sell | $205.51 | -26.66% | 5 | $135.31B |
| BMY | Bristol-Myers Squibb | Hold |
2
|
$44.03 | Buy/Sell | $58.15 | 22.64% | 10 | $89.25B |
| GILD | Gilead Sciences Inc | Outperform |
11
|
$67.72 | Buy/Sell | $87.82 | 18.13% | 14 | $84.36B |
| SHW | Sherwin Williams | Outperform |
15
|
$312.40 | Buy/Sell | $317.38 | 10.90% | 9 | $79.24B |
| LONN | Lonza Group | Buy |
16
|
CHF529.20 | Buy/Sell | CHF516.89 | 13.38% | 8 | CHF38.16B |
| 4502 | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.13k | Buy/Sell | ¥4.74k | 8.96% | 0 | ¥6.48T |
| PPG | PPG Industries | Outperform |
13
|
$134.44 | Buy/Sell | $159.04 | 16.04% | 1 | $31.64B |
| TEVA | Teva Pharmaceutical Industries | Outperform |
12
|
$16.29 | Buy/Sell | $11.59 | 4.36% | 9 | $18.45B |
| 4523 | Eisai | Outperform |
18
|
¥6.78k | Buy/Sell | ¥9.58k | 23.91% | 0 | ¥1.97T |
| INCY | Incyte | Outperform |
9
|
$57.10 | Buy/Sell | $77.05 | 37.48% | 8 | $12.01B |
| CRDA | Croda International Plc | Outperform |
18
|
£47.08 | Buy/Sell | £65.12 | 8.33% | 6 | £6.81B |
| WCH | Wacker Chemie | Outperform |
17
|
103.15€ | Buy/Sell | 145.36€ | 21.18% | 9 | 5.00€B |
| APLS | Apellis Pharmaceuticals | Outperform |
6
|
$41.31 | Buy/Sell | $79.81 | 100.92% | 3 | $5.16B |
| CLN | Clariant | Outperform |
18
|
CHF14.42 | Buy/Sell | CHF16.11 | 10.96% | 6 | CHF4.67B |
| OMER | Omeros | Hold |
11
|
$3.45 | Buy/Sell | $13.00 | -100.00% | 2 | $241.63M |
| XFOR | X4 Pharmaceuticals | Outperform |
4
|
$0.93 | Buy/Sell | $3.26 | 437.63% | 1 | $183.05M |
| DXB | Dimerix |
0
|
$0.38 | Buy/Sell | $0.00 | 52.63% | 0 | $159.38M | |
| IFRX | InflaRx N.V. | Outperform |
4
|
$1.63 | Buy/Sell | $9.44 | 356.44% | 2 | $85.38M |
| BLRX | BioLineRx | - |
7
|
₪0.16 | Buy/Sell | ₪1.39 | -100.00% | 0 | ₪302.07M |
| AKTX | Akari Therapeutics, Plc | - |
2
|
$1.52 | Buy/Sell | $80.00 | -100.00% | 0 | $9.39M |